QR-koodi

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits i...

Täydet tiedot

Tallennettuna:
Päätekijät: Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova, Michel Pavic, April Shamy, Jean Roy, Michael Sebag, Sabrina Trudel, Jean-Sébastien Claveau
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2025-04-01
Sarja:Current Oncology
Aiheet:
bispecific antibodies
multiple myeloma
targeted immunotherapy
toxicity
Linkit:https://www.mdpi.com/1718-7729/32/4/238
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia